Logo

ParAllele Secures $22.5 Million in Private Financing

Sep 23, 2003

NEW YORK, Sept. 23 (GenomeWeb News) - ParAllele BioScience said that it has raised $22.5 million in a round of Series B financing.

The round was led by a new investor, Mohr, Davidow Ventures, and included such existing investors as Abingworth Management, Index Ventures, and Versant Ventures.

Proceeds of the financing, said ParAllele, will be used to support the ongoing development and roll out of the company's SNP products.

Breaking News
The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.